Revolution Medicines, Inc. (RVMD) Tops Q3 EPS by 200c

Revolution Medicines, Inc. (NASDAQ: RVMD) reported Q3 EPS of $0.99, $2.00 better than the analyst estimate of ($1.01). Revenue for the quarter came in at $0 versus the consensus estimate of $750 thousand.

For earnings history and earnings-related data on Revolution Medicines, Inc. (RVMD) click here.

You May Also Be Interested In

• Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
• AeroVironment (AVAV) Tops Q4 EPS by 36c
• SanDisk (SNDK) PT Raised to $3,000 at Bernstein SocGen Group, 'We believe this is not understood by the Street'